DIAKO Evangelisches Diakonie-Krankenhaus gGmbH

Hospital


Location: Bremen, Germany (DE) DE

ISNI: 0000000405581414

ROR: https://ror.org/04tsv5127

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Kurzversion (2025) Groβ S, Bitzer M, Albert J, Blödt S, Boda-Heggemann J, Borucki K, Brunner T, et al. Journal article Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial (2022) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duehrsen U, Hahn D, Meidenbauer N, et al. Journal article S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome (2022) Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, et al. Journal article S3 Guideline - Diagnosis and treatment of biliary carcinomas: Long version 2.0 - June 2021 - AWMF Register No.: 032-053OL S3-Leitlinie - Diagnostik und Therapie biliärer Karzinome (2022) Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, et al. Journal article Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry (2022) Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schaefer-Eckart K, Steffen B, Sauer T, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article Modified Risk-Stratified Sequential Treatment in B-Cell Post-Transplant Lymphoproliferative Disorder (PTLD) after Solid Organ Transplantation (SOT): The Prospective Multicenter Phase II PTLD-2 Trial (2021) Zimmermann H, Koenecke C, Dreyling MH, Pott C, Duhrsen U, Hahn D, Meidenbauer N, et al. Conference contribution Patient-reported treatment satisfaction with Rivaroxaban in cancer patients with acute venous thromboembolism - Results from the CONKO-011 trial (2021) Sinn M, Juehling A, Hellmann M, Omar M, Suedhoff T, Stahl M, Krziwanie A, et al. Conference contribution Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas (2021) Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, et al. Journal article Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial (2021) Röllig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus CD, Brandts CH, et al. Journal article